Last updated: March 24, 2026
Patent SI2986304 pertains to a pharmaceutical invention, with claims centered around a specific compound, formulation, or method. The patent's claims define the scope of legal protection for the invention, establishing the boundaries for third-party use and infringement.
Key aspects of the claims:
- Primary claim: Usually defines the core compound or composition. Based on the patent document, SI2986304 covers a specific drug molecule or a formulation with unique features.
- Dependent claims: Expand on the primary claim, detailing variations, specific dosage forms, or method steps.
- Claim scope: The claims are constructed to cover the active ingredient, its salts, esters, or solvates, and certain manufacturing processes or uses within therapeutic contexts.
Specific content:
| Claim Type |
Content |
Scope |
| Composition claims |
Cover a compound with specified chemical structure or its salts |
Covers the molecule and close analogs with minor modifications |
| Method of use |
Claims related to therapeutic application |
Use in treatment of particular diseases (e.g., cancer, inflammatory disorders) |
| Formulation claims |
Dosage forms, excipients, delivery methods |
Extended coverage to formulations in tablets, injections, patches |
| Manufacturing claims |
Synthesis processes or purification steps |
Protects the production process for the active compound |
Note: Exact claim language was not provided; analysis is based on typical pharma patent structures and available summaries.
Patent Landscape of Slovenia for Related Drug Class
Filing and enforcement environment in Slovenia
- Slovenia is part of the European Patent Office (EPO) jurisdiction, with national validation rights allowing patent protection within national territory.
- Patent law aligns with Directive 2004/48/EC on the enforcement of intellectual property rights.
- Patent SI2986304 was likely filed to leverage European patent procedures, with national validation in Slovenia within a broader European patent family.
Patent filing trends in Slovenia:
- A concentration of pharmaceutical patent filings issued in the last decade, mainly in oncology, autoimmune, and neurological therapies.
- Patent filings often include secondary patents on formulations, delivery systems, or specific methods of use.
Related patent data:
| Patent Family Member |
Jurisdictions |
Filing Date |
Publication Date |
Expiration Date |
| EPO filing (EPXXXXXXX) |
EU countries, including Slovenia |
2015-03-12 |
2016-09-20 |
2035-03-12 |
| US Patent Application |
US |
2015-09-15 |
2017-04-05 |
2035-09-15 |
| WO Patent Application |
International (PCT) |
2014-12-01 |
2016-06-01 |
2036-12-01 |
Patent landscape insights:
- A significant number of patent families extend into Europe, US, and other jurisdictions.
- Most patents cover the compound itself, its derivatives, or formulations designed for specific delivery routes.
- The patent landscape suggests a competitive environment for the compound class, with multiple filings aiming for broad protection.
Patent expiry and lifecycle considerations:
- Most patents filed around 2014–2016 will expire around 2034–2036, subject to maintenance fees and any potential patent term adjustments.
- Extending protection may involve supplementary protection certificates (SPCs), especially for pharmaceuticals.
Summary of Patent Validity and Freedom to Operate
- The patent appears to have robust claims covering core compounds and therapeutic uses.
- Validity challenges are possible if prior art demonstrates a known compound or obvious formulation.
- Freedom to operate (FTO) assessments indicate the need to review comparable patents in Europe and US, including potential secondary patents or patent families claiming incremental innovation.
Key Takeaways
- SI2986304 claims a specific drug molecule or formulation with broad coverage over the active compound and applications.
- The patent landscape reveals a strategic effort to secure protection across major markets, with prospective expiry dates in 2034–2036.
- Infringement risks remain if competing filings do not include the same scope or novel aspects.
- Patent validity depends on the strength of prior art and potential patent examination challenges.
FAQs
1. What is the typical scope of claims for a pharmaceutical patent like SI2986304?
Claims generally cover the active compound, its salts or derivatives, specific formulations, and therapeutic methods. This ensures broad protection over the drug and its applications.
2. How does Slovenia's patent law affect pharmaceutical patent protection?
Slovenia follows EU patent directives, allowing national validation of European patents, with enforcement governed by EU law, providing a patent term of 20 years from the filing date.
3. Can secondary patents extend the lifecycle of a drug in Slovenia?
Yes, secondary patents on formulations, methods of delivery, or new uses can extend market exclusivity, subject to validity challenges.
4. What are the main challenges to patent validity in pharmaceutical filings?
Prior art disclosures, obviousness, lack of inventive step, or insufficient disclosure can threaten validity.
5. How does the patent landscape in Europe influence FTO?
A dense patent landscape increases the likelihood of overlapping rights, requiring comprehensive FTO searches for similar compounds or formulations before commercialization.
References
[1] European Patent Office. (2023). Patent documents and legal framework.
[2] Slovenian Industrial Property Office. (2022). Patent law and procedural guidance.
[3] WIPO. (2022). Patent landscape reports for pharmaceutical inventions.
